The outcomes from the Phase III IMROZ study support the decision. Sanofi Oncology global head Olivier Nataf stated: “In recent years, new multiple myeloma cases have increased steadily in Japan ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction with bortezomib, lenalidomide and dexamethasone (VRd) to treat ...

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and ...

in the IMROZ study, which is also due for presentation at ASH. “Effective front-line treatment is critical for newly diagnosed patients, because achieving undetectable levels of disease early in ...

Improve your local SEO with Schema. Get noticed in search results and increase visibility with structured data. Structured data markup can work diligently behind the scenes to help your local ...

The FDA’s review is based mainly on the phase 3 IMROZ study, which met the primary endpoint with a 40% improvement in progression-free survival compared with VRd alone, which the trial ...

All De Montfort University (DMU) students belong to one of four faculties. Each faculty delivers a wide range of courses to students as well as overseeing world-changing research and fostering ...

according to the results of a new study. The findings suggest -- for the first time in a clinical trial -- that early treatment to remove amyloid plaques from the brain many years before symptoms ...

The outcomes from the Phase III IMROZ study support the decision. Sanofi Oncology global head Olivier Nataf stated: “In recent years, new multiple myeloma cases have increased steadily in Japan and ...